April 20, 2024
Bio
Daewoong Pharma’s antibiotics launched in US
[THE INVESTOR] Daewoong Pharmaceutical said on April 19 that its generic antibiotic Meropenem has hit shelves in the US.
Meropenem, which is used in treatment for a wide range of diseases ranging from serious bacterial infection to general infection, was rolled out under the name Daewoong Meropenem Inj in the world’s largest pharma market, it said.
In December 2012, the US Food and Drug Administration accepted Daewoong Pharma’s application to sell the antibiotic, which is in reference to multinational pharmaceutical company AstraZeneca’s Merrem.
It marks the first time for a generic drug manufactured by a local drug firm to be sold in the US, company officials said.
“The company hopes the launch of Meropenem will boost the image of South Korean pharmaceutical companies in the US drug market. The company will step up efforts to bring internationally competitive products,” said Lee Jong-wook, vice president of Daewoong Pharma, in a press release.
By Alex Lee and newswires (alexlee@heraldcorp.com)
Meropenem, which is used in treatment for a wide range of diseases ranging from serious bacterial infection to general infection, was rolled out under the name Daewoong Meropenem Inj in the world’s largest pharma market, it said.
In December 2012, the US Food and Drug Administration accepted Daewoong Pharma’s application to sell the antibiotic, which is in reference to multinational pharmaceutical company AstraZeneca’s Merrem.
It marks the first time for a generic drug manufactured by a local drug firm to be sold in the US, company officials said.
“The company hopes the launch of Meropenem will boost the image of South Korean pharmaceutical companies in the US drug market. The company will step up efforts to bring internationally competitive products,” said Lee Jong-wook, vice president of Daewoong Pharma, in a press release.
By Alex Lee and newswires (alexlee@heraldcorp.com)
